OliX Pharmaceuticals, Inc (KOSDAQ:226950)
102,200
-3,900 (-3.68%)
Sep 22, 2026, 3:30 PM KST
OliX Pharmaceuticals Revenue
OliX Pharmaceuticals had revenue of 2.62B KRW in the quarter ending June 30, 2026, a decrease of -58.02%. This brings the company's revenue in the last twelve months to 13.64B, up 80.93% year-over-year. In the year 2025, OliX Pharmaceuticals had annual revenue of 14.67B with 158.35% growth.
Revenue (ttm)
13.64B
Revenue Growth
+80.93%
P/S Ratio
177.02
Revenue / Employee
n/a
Employees
n/a
Market Cap
2.41T
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 14.67B | 8.99B | 158.35% |
| Dec 31, 2024 | 5.68B | -11.39B | -66.73% |
| Dec 31, 2023 | 17.06B | 7.74B | 83.09% |
| Dec 31, 2022 | 9.32B | 5.65B | 153.66% |
| Dec 31, 2021 | 3.67B | 1.20B | 48.50% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| SK Biopharmaceuticals | 861.34B |
| SK bioscience | 659.27B |
| Hugel | 479.57B |
| LigaChem Biosciences | 98.78B |
| HLB Co., Ltd. | 97.47B |
| ABL Bio | 34.28B |
| Peptron | 6.00B |
| Kolon TissueGene | 4.80B |